(Q33209050)

23 July 2017

1 reference

title

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? (English)

1 reference

23 July 2017

1 reference

1

Ludwig Kappos

1 reference

23 July 2017

Jens Kuhle

2

1 reference

23 July 2017

Achim Gass

series ordinal

3

1 reference

23 July 2017

Lutz Achtnichts

series ordinal

4

1 reference

23 July 2017

Ernst-Wilhelm Radue

series ordinal

5

1 reference

23 July 2017

publication date

1 September 2004

1 reference

23 July 2017

1 reference

23 July 2017

volume

251 Suppl 5

1 reference

23 July 2017

page(s)

v57-v64

1 reference

Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin

23 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-004-1509-6

Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis

21 January 2018

1 reference

12 December 2020

Demyelination: the role of reactive oxygen and nitrogen species

1 reference

12 December 2020

Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Rapamycins: mechanism of action and cellular resistance

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Attenuation of experimental autoimmune encephalomyelitis and nonimmune demyelination by IFN-beta plus vitamin B12: treatment to modify notch-1/sonic hedgehog balance

1 reference

12 December 2020

Multiple approaches to multiple sclerosis

1 reference

12 December 2020

Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment

1 reference

12 December 2020

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

1 reference

12 December 2020

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone

1 reference

12 December 2020

The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration

1 reference

12 December 2020

Stem cell transplantation for multiple sclerosis: What is the evidence?

1 reference

12 December 2020

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

1 reference

12 December 2020

Macrophages: their myelinotrophic or neurotoxic actions depend upon tissue oxidative stress

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents

1 reference

12 December 2020

Glutamate excitotoxicity in a model of multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

1 reference

12 December 2020

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b

1 reference

12 December 2020

The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment

1 reference

12 December 2020

Anticonvulsants in central pain

1 reference

12 December 2020

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

12 December 2020

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

1 reference

12 December 2020

Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease.

1 reference

12 December 2020

In vivo damage of CNS myelin and axons induced by peroxynitrite

1 reference

12 December 2020

Natalizumab for active Crohn's disease

1 reference

12 December 2020

An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

1 reference

12 December 2020

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy

1 reference

12 December 2020

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

1 reference

12 December 2020

Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells

1 reference

12 December 2020

Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases

1 reference

12 December 2020

Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Autoimmune encephalomyelitis ameliorated by AMPA antagonists

1 reference

12 December 2020

10.1007/S00415-004-1509-6

Identifiers

DOI

1 reference

Dimensions Publication ID

23 July 2017

1051103727

0 references

1 reference